Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Biogen Idec reports earnings

BIIB posted 3Q07 non-GAAP diluted EPS of $0.58, down 3% from $0.60 in 3Q06. The 2007 figure includes an $0.11 per share R&D expense related to BIIB's July

Read the full 283 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE